Related Experiment Video
Updated: May 4, 2026

Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
Published on: May 21, 2018
Inflammasome-independent IL-1β mediates autoinflammatory disease in Pstpip2-deficient mice
Suzanne L Cassel1, John R Janczy, Xinyu Bing
1Inflammation Program, Department of Internal Medicine, Graduate Program in Immunology, Department of Pediatrics, Department of Pathology, Department of Orthopedics, Dows Institute for Dental Research and Department of Periodontics, College of Dentistry, and Department of Epidemiology, University of Iowa, Iowa City, IA 52242.
Abstract:
Chronic recurrent multifocal osteomyelitis (CRMO) is a human autoinflammatory disorder that primarily affects bone. Missense mutation (L98P) of proline-serine-threonine phosphatase-interacting protein 2 (Pstpip2) in mice leads to a disease that is phenotypically similar to CRMO called chronic multifocal osteomyelitis (cmo). Here we show that deficiency of IL-1RI in cmo mice resulted in a significant reduction in the time to onset of disease as well as the degree of bone pathology. Additionally, the proinflammatory cytokine IL-1β, but not IL-1α, played a critical role in the pathology observed in cmo mice. In contrast, disease in cmo mice was found to be independent of the nucleotide-binding domain, leucine-rich repeat-containing family, pyrin domain-containing 3 (NLRP3) inflammasome as well as caspase-1. Neutrophils, but not bone marrow-derived macrophages, from cmo mice secreted increased IL-1β in response to ATP, silica, and Pseudomonas aeruginosa compared with neutrophils from WT mice. This aberrant neutrophil response was sensitive to inhibition by serine protease inhibitors. These results demonstrate an inflammasome-independent role for IL-1β in disease progression of cmo and implicate neutrophils and neutrophil serine proteases in disease pathogenesis. These data provide a rationale for directly targeting IL-1RI or IL-1β as a therapeutic strategy in CRMO.
Insights
Chronic recurrent multifocal osteomyelitis (CRMO) involves bone inflammation. Targeting IL-1RI or IL-1β shows therapeutic potential by reducing disease severity and pathology in a mouse model.
Area of Science:
- Immunology
- Bone Biology
- Autoinflammatory Diseases
Background:
- Chronic recurrent multifocal osteomyelitis (CRMO) is a rare autoinflammatory bone disease.
- A mouse model with a Pstpip2 mutation mimics CRMO, termed chronic multifocal osteomyelitis (cmo).
Purpose of the Study:
- To investigate the role of IL-1 receptor 1 (IL-1RI) and IL-1β in CRMO pathogenesis.
- To explore the involvement of neutrophils and inflammasomes in the disease model.
Main Methods:
- CRMO mouse models were studied with and without IL-1RI.
- Cytokine levels (IL-1β, IL-1α) and inflammasome components (NLRP3, caspase-1) were analyzed.
- Neutrophil and macrophage inflammatory responses were assessed.
Main Results:
- IL-1RI deficiency accelerated disease onset and reduced bone pathology in cmo mice.
- IL-1β, not IL-1α, was critical for disease progression, independent of NLRP3 inflammasome activation.
- Neutrophils from cmo mice showed heightened IL-1β secretion, sensitive to serine protease inhibitors.
Conclusions:
- IL-1β plays a key role in CRMO pathogenesis through an inflammasome-independent pathway.
- Neutrophils and neutrophil serine proteases are implicated in CRMO development.
- Targeting IL-1RI or IL-1β offers a potential therapeutic strategy for CRMO.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
The JAK-STAT Signaling Pathway
Inflammatory Bowel Disease II: Ulcerative Colitis
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

